AHCO Stock Analysis: Adapthealth | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.464m USD | 12M Return: 8.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.6M
Qual. Beats: 0
Rev. Trend: -80.4%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AdaptHealth Corp. (NASDAQ: AHCO) is a U.S. distributor of home medical equipment (HME), medical supplies, and related home-based services, operating through four segments: Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home. The company provides sleep therapy devices (such as CPAP and BiLevel machines) for obstructive sleep apnea, oxygen and home mechanical ventilation equipment, continuous glucose monitors and insulin pumps for diabetes management, and a wide range of HME including wheelchairs, hospital beds, breast pumps, wound care, and incontinence supplies. AdaptHealth serves patients discharged from acute care facilities and others receiving care at home, with revenue largely tied to reimbursement from Medicare, Medicaid, and commercial insurance payors. Founded in 2012 and headquartered in Conshohocken, Pennsylvania, the company went public in 2018 and is classified as a small-cap stock within the Health Care Distributors sub-industry.
As a healthcare distributor focused on home-based care, AdaptHealth operates in a sector whose demand is shaped by demographic aging, the ongoing shift of care from inpatient to home settings, and reimbursement policy decisions from major government payors like Medicare, which together account for a significant share of industry revenue.
- Sleep resupply softness pressures largest revenue segment
- Medicare competitive bidding cuts compress HME margins
- Diabetes Health scales on continuous glucose monitor adoption
| Net Income: -79.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.85 > 1.0 |
| NWC/Revenue: -1.95% < 20% (prev 6.41%; Δ -8.36% < -1%) |
| CFO/TA 0.14 > 3% & CFO 600.0m > Net Income -79.6m |
| Net Debt (2.13b) to EBITDA (462.5m): 4.61 < 3 |
| Current Ratio: 0.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (135.8m) vs 12m ago 0.73% < -2% |
| Gross Margin: 5.38% > 18% (prev 4.75%; Δ 0.63% > 0.5%) |
| Asset Turnover: 64.56% > 50% (prev 59.26%; Δ 5.30% > 0%) |
| Interest Coverage Ratio: 0.49 > 6 (EBIT TTM 50.5m / Interest Expense TTM 102.9m) |
| A: -0.01 (Total Current Assets 687.5m - Total Current Liabilities 743.3m) / Total Assets 4.42b |
| B: -0.15 (Retained Earnings -649.0m / Total Assets 4.42b) |
| C: 0.01 (EBIT TTM 50.5m / Avg Total Assets 4.43b) |
| D: 0.52 (Book Value of Equity 1.51b / Total Liabilities 2.91b) |
| Altman-Z'' = 0.06 = B |
| DSRI: 0.86 (Receivables 392.0m/418.5m, Revenue 2.86b/2.63b) |
| GMI: 0.88 (GM 4.75% / 5.38%) |
| AQI: 0.96 (AQ_t 0.66 / AQ_t-1 0.69) |
| SGI: 1.09 (Revenue 2.86b / 2.63b) |
| TATA: -0.15 (NI -79.6m - CFO 600.0m) / TA 4.42b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 10.22 with a total of 1,090,507 shares traded. Over the past week, the price has changed by -5.02%, over one month by +2.92%, over three months by -16.02% and over the past year by +8.15%.
Current recommended Stop Loss: 9.30 (which is 9% or 2.4 ATR below the current price).
Adapthealth has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy AHCO.
- StrongBuy: 5
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14 | 37% |
P/E Forward = 12.6904
P/S = 0.4454
P/B = 0.9565
Revenue TTM = 2.86b USD
EBIT TTM = 50.5m USD
EBITDA TTM = 462.5m USD
Long Term Debt = 1.80b USD (from longTermDebt, last quarter)
Short Term Debt = 78.3m USD (from shortTermDebt, last quarter)
Debt = 2.18b USD (from shortLongTermDebtTotal, last quarter) + Leases 177.4m
Net Debt = 2.13b USD (calculated: Debt 2.18b - CCE 48.0m)
Enterprise Value = 3.59b USD (1.46b + Debt 2.18b - CCE 48.0m)
Interest Coverage Ratio = 0.49 (Ebit TTM 50.5m / Interest Expense TTM 102.9m)
EV/FCF = 18.72x (Enterprise Value 3.59b / FCF TTM 192.0m)
FCF Yield = 5.34% (FCF TTM 192.0m / Enterprise Value 3.59b)
FCF Margin = 6.71% (FCF TTM 192.0m / Revenue TTM 2.86b)
Net Margin = -2.78% (Net Income TTM -79.6m / Revenue TTM 2.86b)
Gross Margin = 5.38% ((Revenue TTM 2.86b - Cost of Revenue TTM 2.71b) / Revenue TTM)
Gross Margin QoQ = 12.37% (prev 19.17%)
Tobins Q-Ratio = 0.81 (Enterprise Value 3.59b / Total Assets 4.42b)
Interest Expense / Debt = 4.73% (Interest Expense 102.9m / Debt 2.18b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 39.9m (EBIT 50.5m * (1 - 21.00%))
Current Ratio = 0.92 (Total Current Assets 687.5m / Total Current Liabilities 743.3m)
Debt / Equity = 1.45 (Debt 2.18b / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 4.61 (Net Debt 2.13b / EBITDA 462.5m)
Debt / FCF = 11.10 (Net Debt 2.13b / FCF TTM 192.0m)
Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.80% (Net Income -79.6m / Total Assets 4.42b)
RoE = -5.11% (Net Income TTM -79.6m / Total Stockholder Equity 1.56b)
RoCE = 1.50% (EBIT 50.5m / Capital Employed (Equity 1.56b + L.T.Debt 1.80b))
RoIC = 1.07% (NOPAT 39.9m / Invested Capital 3.71b)
WACC = 5.59% (E(1.46b)/V(3.64b) * Re(8.36%) + D(2.18b)/V(3.64b) * Rd(4.73%) * (1-Tc(0.21)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 29.02 | Cagr: 0.66%
[DCF] Terminal Value 73.10% ; FCFF base≈225.0m ; Y1≈197.3m ; Y5≈159.4m
[DCF] Fair Price = 3.15 (EV 2.56b - Net Debt 2.13b = Equity 428.7m / Shares 136.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.74 | # QB: 0
Revenue Correlation: -80.41 | Revenue CAGR: -9.37% | SUE: 0.23 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.15 | Chg30d=+0.00% | Revisions=-38% | Analysts=6
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=+0.00% | Revisions=+12% | Analysts=6
EPS current Year (2026-12-31): EPS=0.84 | Chg30d=+0.00% | Revisions=-38% | GrowthEPS=+54.9% | GrowthRev=+7.5%
EPS next Year (2027-12-31): EPS=1.18 | Chg30d=+0.14% | Revisions=+0% | GrowthEPS=+39.9% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: -23% (up=7, down=12)